Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 79,221	$ 228,182
Marketable securities	223,142	155,067
Prepaid expenses and other current assets	8,640	10,354
Other receivable	1,770	6,044
Total current assets	312,773	399,647
Restricted cash, non-current	73	20,000
Property and equipment, net	3,116	1,882
Operating lease right-of-use assets	3,978	4,763
Other non-current assets	20	51
Total assets	319,960	426,343
Current liabilities:
Accounts payable	1,453	3,231
Accrued expenses	19,826	9,976
Current portion of operating lease liabilities	1,851	1,125
Other current liabilities	485	760
Total current liabilities	23,615	15,092
Operating lease liabilities	2,488	3,709
Other liabilities	210	206
Nonrefundable research deposit	0	20,000
Total liabilities	26,313	39,007
Commitments and contingencies (Note 8)
Shareholders’ equity (deficit):
Ordinary shares, $0.000017100448 par value. Authorized 2,923,900,005 shares as of December 31, 2022; 107,043,924 shares issued and outstanding at December 31, 2022; Authorized 2,923,900,005 shares as of December 31, 2021; 107,275,458 shares issued and outstanding at December 31, 2021	2	2
Additional paid-in capital	732,476	713,269
Accumulated other comprehensive (loss) income	(2,080)	526
Accumulated deficit	(470,525)	(360,235)
Total LianBio shareholders’ equity	259,873	353,562
Non-controlling interest	33,774	33,774
Total shareholders’ equity	293,647	387,336
Total liabilities and shareholders’ equity	$ 319,960	$ 426,343